Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials

References

• SiegelRLMillerKDJemalACancer Statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyBreast Cancer Facts and Figures 2013–2014 Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdfAccessed February 11, 2015
   Google Scholar
• PujolPDauresJPThezenasSGuilleuxFRouanetPGrenierJChanging estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopauseCancer19988346987059708933
   PubMed Web of Science ®Google Scholar
• PartonMDowsettMSmithIStudies of apoptosis in breast cancerBMJ200132273011528153211420276
   PubMed Web of Science ®Google Scholar
• OsborneCKTamoxifen in the treatment of breast cancerN Engl J Med199833922160916189828250
   PubMed Web of Science ®Google Scholar
• KlijnJGBeexLVMauriacLCombined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized studyJ Natl Cancer Inst2000921190391110841825
   PubMedGoogle Scholar
• MitsuyamaSNomuraYOhnoSAssessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan – Zoladex Breast Cancer Study Group Trial-BGan To Kagaku Ryoho2005321320712077 Japanese16352931
   PubMedGoogle Scholar
• BaumMHackshawAHoughtonJZIPP International Collaborators Group. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP studyEur J Cancer200642789590416545560
   PubMed Web of Science ®Google Scholar
• The Adjuvant Breast Cancer Trials Collaborative GroupOvarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trialJ Natl Cancer Inst200799751652517405996
   PubMedGoogle Scholar
• CuzickJAmbroisineLDavidsonNUse of luteinizing-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trialsLancet200736995741711172317512856
   PubMed Web of Science ®Google Scholar
• KlijnJGBlameyRWBoccardoFCombined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trialsJ Clin Oncol200119234335311208825
   PubMed Web of Science ®Google Scholar
• CrumpMSawkaCADeBoerGAn individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancerBreast Cancer Res Treat19974432012109266099
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJIngleJMeta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenJ Clin Oncol201028350951819949017
   PubMed Web of Science ®Google Scholar
• TevaarwerkAJWangMZhaoFPhase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in pre-menopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology GroupJ Clin Oncol201432353948395825349302
   PubMed Web of Science ®Google Scholar
• FrancisPAReganMMFlemingGFAdjuvant ovarian suppression in premenopausal breast cancerN Engl J Med2015372543644625495490
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0The Cochrane Collaboration2011 Available from: http://handbook.cochrane.org/Accessed May 17, 2015
   Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• DavidsonNEO’NeillAMVukovAMChemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)J Clin Oncol200523255973598216087950
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAAmorosoDCyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trialJ Clin Oncol200018142718272710894871
   PubMed Web of Science ®Google Scholar
• ParidaensRJGelberSColeBFAdjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerBreast Cancer Res Treat2010123130331020195744
   PubMed Web of Science ®Google Scholar
• JakeszRHausmaningerHKubistaERandomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group Trial 5J Clin Oncol200220244621462712488405
   PubMed Web of Science ®Google Scholar
• YangHZongXYuYCombined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trialBr J Cancer2013109358258823860520
   PubMed Web of Science ®Google Scholar
• ColeMPJonesCTToddIDA new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474Br J Cancer19712522702755115829
   PubMed Web of Science ®Google Scholar
• KisangaERGjerdeJSchjøttJMellgrenGLienEATamoxifen administration and metabolism in nude mice and nude ratsJ Steroid Biochem Mol Biol2003842–336136712711024
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupTamoxifen for early breast cancer: an overview of the randomised trialsLancet19983519114145114679605801
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); DaviesCGodwinJGrayRRelevance of breast cancer hormone receptors and other factors to the effıcacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• GrayRGReaDHandleyKaTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancerJ Clin Oncol20133118 Suppl Abstr 5
   Web of Science ®Google Scholar
• SchinzingerA[About breast carcinoma]. Abstract presented at the 18th Congress of the German Society for SurgeryZentralbl Chir188916Suppl5566 German
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 womenLancet199233987841151345950
   PubMed Web of Science ®Google Scholar
• ArriagadaRLêMGSpielmannMRandomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapyAnn Oncol200516338939615677625
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Study Group (IBCSG)Castiglione-GertschMO’NeillAPriceKNAdjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trialJ Natl Cancer Inst200395241833184614679153
   PubMedGoogle Scholar
• RecchiaFSaggioGAmiconiGGonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinomaCancer2006106351452316388519
   PubMed Web of Science ®Google Scholar
• KhanSSKarnTSymmansWFGenomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancersBreast Cancer Res Treat2015149378979725651779
   PubMed Web of Science ®Google Scholar
• ArriagadaRRutqvistLEMattssonAKramarARotsteinSAdequate locoregional treatment for early breast cancer may prevent secondary disseminationJ Clin Oncol19951312286928788523049
   PubMed Web of Science ®Google Scholar
• FortinALarochelleMLaverdièreJLavertuSTremblayDLocal failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapyJ Clin Oncol199917110110910458223
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupForbesJFCuzickJBuzdarAHowellATobiasJSBaumMEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol200891455318083636
   PubMed Web of Science ®Google Scholar
• CoatesASKeshaviahAThurlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98J Clin Oncol200725548649217200148
   PubMed Web of Science ®Google Scholar
• van de VeldeCJReaDSeynaeveCAdjuvant Tamoxifen and Exemestane in Early Breast Cancer (TEAM): a randomised phase 3 trialLancet2011377976232133121247627
   PubMed Web of Science ®Google Scholar
• PaganiOReganMMWalleyBATEXT and SOFT Investigators; International Breast Cancer Study GroupAdjuvant exemestane with ovarian suppression in premenopausal breast cancerN Engl J Med2014371210711824881463
   PubMed Web of Science ®Google Scholar